Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665
Journal of Surgical Oncology2008Vol. 99(1), pp. 42–47
Citations Over TimeTop 1% of 2008 papers
Burton Eisenberg, Jonathan Harris, Charles D. Blanke, George D. Demetri, Michael C. Heinrich, James C. Watson, John P. Hoffman, Scott H. Okuno, John M. Kane, Margaret von Mehren
Abstract
This trial represents the first prospective report of preop IM in GIST. This approach is feasible, requires multidisciplinary consultations, and is not associated with notable postop complications.
Related Papers
- → Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients(2003)143 cited
- → The role of imatinib plasma level testing in gastrointestinal stromal tumor(2010)18 cited
- → Gastrointestinal Stromal Tumor (GIST) - Single Center Experience of prolonged treatment with Imatinib(2005)13 cited
- → Imatinib Dose Interruption in GIST: High Progression Risk for 3-YearResponders(2007)
- Research Progress of Imatinib Preoperative Chemotherapy in Treatment of Advanced Gastrointestinal Stromal Tumor(2014)